Ibrutinib plus chemoimmunotherapy improved PFS for newly diagnosed MCL

Bookmark and Share
Published: 3 Jun 2022
Views: 49
Rating:
Save

Dr Michael Wang discusses the primary results from the double‐blind, placebo‐controlled, phase III SHINE study of ibrutinib in combination with bendamustine‐ rituximab and R maintenance as a first‐line treatment for older patients with mantle cell lymphoma.

Initially Dr Wang talks about the background and the methodology of the study. This randomised Phase III SHINE clinical trial was conducted at 183 sites in 28 countries since 2013. The double-blinded study evaluated treatment with bendamustine-rituximab and rituximab maintenance plus either ibrutinib or placebo. The primary endpoint was progression-free survival (PFS) assessed by the investigators.

He then explains the results of this trial. The median PFS was 80.6 months with the ibrutinib combination versus 52.9 months in the control arm. The complete response rate was 65.5% in the ibrutinib arm and 57.6% in the placebo arm. Median overall survival had not been reached in either treatment arm at the time of data cutoff.

Dr Wang says “These results provide evidence that an ibrutinib-based combination front-line treatment regimen provides a significant progression-free survival benefit and may be a new treatment opportunity for this patient population who previously had few options.”

The patients in this study continue to be followed to evaluate differences in overall survival between treatment arms. Future research may investigate chemotherapy-free or time-limited ibrutinib combinations.

Source: ASCO

Watch the interview here

Read the article here

Related Videos

Efficacy and safety of ARI0002H, a BCMA-directed CAR-T cell therapy with fractio...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain
Efficacy and safety of ARI0002H, a BCMA-directed CAR-T cell therapy with fractionated initial therapy and booster dose in RRMM ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain )
14 Jun 2022
Safety and efficacy of the bispecific antibody talquetamab in relapsed/refractor...
Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands
Safety and efficacy of the bispecific antibody talquetamab in relapsed/refractory multiple myeloma ( Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands )
13 Jun 2022
Ponatinib and blinatumomab for patients with Philadelphia chromosome-positive AL...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Ponatinib and blinatumomab for patients with Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
13 Jun 2022
Subcutaneous isatuximab administration by an on-body delivery system in combinat...
Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia
Subcutaneous isatuximab administration by an on-body delivery system in combination with pomalidomide-dexamethasone in RRMM ( Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia )
13 Jun 2022
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in ...
Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL ( Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany )
13 Jun 2022
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with ...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain )
13 Jun 2022
A single dose of ctx001 shows promising efficacy and safety for TDT and severe S...
Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy
A single dose of ctx001 shows promising efficacy and safety for TDT and severe SCD ( Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy )
13 Jun 2022
Treatment with decitabine resulted in a similar survival and fewer adverse event...
Prof Michael Lübbert - Universitätsklinikum Freiburg, Freiburg, Germany
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with chemo in older patients with AML ( Prof Michael Lübbert - Universitätsklinikum Freiburg, Freiburg, Germany )
13 Jun 2022
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...
Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
7 Jun 2022